Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: An evaluation using the cardio-ankle vascular index (CAVI)

Journal of International Medical Research

Volumn 36, Issue 5, 2008, Pages 1094-1102

  Uehara, G ^a   Takeda, Hiroshi ^a  

^a Takeda Clinic   (Japan)

Author keywords

Angiotensin receptor blockers; Arteriosclerosis; Candesartan; Cardioankle vascular index; CAVI; Losartan; Peroxisome proliferator activated receptor ; PPAR ; Telmisartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; INSULIN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFONYLUREA DERIVATIVE; TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ANALYTIC METHOD; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; TREATMENT DURATION; AGED; ANIMAL; ANKLE; BLOOD PRESSURE; COMORBIDITY; DRUG POTENTIATION; HEART; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VASCULAR RESISTANCE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANKLE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HEART; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PPAR GAMMA; TETRAZOLES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 54449090024     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600529     Document Type: Article

References (35)

1. American Diabetes Association: Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29(suppl 1): S4-S42.
2. Zieman SJ, Melenovsky V, Kass DA: Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 932-943.
3. Lee A, Cerami A: Role of glycation in aging. Ann NY Acad Sci 1992; 663: 63-70.
4. Yan SD, Schmidt AM, Anderson GM, et al: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
5. Dzau VJ: Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8: 553-559.
6. 1 receptors in experimental and human hypertension. Can J Physiol Pharmacol 1996; 74: 862-866.
7. Kato H, Suzuki H, Tajima S, et al: Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9: 17-22.
8. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
9. Rosen ED, Spiegelman BM: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-37734.
10. Diep QN, El Marouk M, Cohn JS: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats. Role of peroxisome proliferator-activated receptor-γ. Circulation 2002; 105: 2296-2302.
11. Sugawara A, Takeuchi K, Uruno A: Effects of mitogen-activated protein kinase pathway and co-activator CREP-binding protein on peroxisome proliferator-activated receptor-γ-mediated transcription suppression of angiotensin II type 1 receptor gene. Hypertens Res 2003; 26: 623-628.
12. Schupp M, Janke J, Clasen R: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109: 2054-2057.
13. Benson SC, Pershadsingh HA, Ho CI: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ-modulating activity. Hypertension 2004; 43: 993-1002.
14. Oliver JJ, Webb DJ: Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23: 554-566.
15. Laurent S, Boutouyrie P, Asmar R: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
16. Asmar R, Benetos A, Topouchian J, et al: Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995; 26: 485-490.
17. Shirai K, Utino J, Otsuka K: A novel blood pressure-independent arterial wall stiffness parameter: cardio-ankle vascular index. J Atheroscler Thromb 2006; 13: 101-107.
18. Wakabayashi I, Masuda H: Effects of age on the relationship between cardio-ankle vascular index and atherosclerotic progression in patients with type 2 diabetes mellitus. Jpn J Geriatr 2006; 43: 217-221.
19. Okura T, Watanabe S, Kurata M, et al: Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res 2007; 30: 335-340.
20. Yambe T, Yoshizawa M, Saijo Y, et al: Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 2004; 58: S95-S98.
21. Huck CJ, Bronas UG, Williamson EB, et al: Noninvasive measurements of arterial stiffness: repeatability and interrelationships with endothelial function and arterial morphology measures. Vasc Health Risk Manag 2003; 23: 343-349.
22. Shirai K: CAVI, a new index of arteriosclerosis and coronary artery disease. Jpn Med J 2007; 4334: C1-C4.
23. Asmar R, Gosse P, Topouchian J: Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst. 2002; 3: 176-180.
24. Sasamura H, Kitamura Y, Nakamura M: Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens 2006; 28: 511-520.
25. Agata J, Nagahara D, Kinoshita S: Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 2004; 68: 1194-1198.
26. Uchida H, Nakamura Y, Makino H, et al: Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545-550.
27. Nakamura T, Yamamoto E, Kim-Mitsuyama S, et al: Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51: 296-301.
28. Ogihara T, Minami F, Kainuma H: Pharmacokinetic evaluation of angiotensin II AT1 receptor antagonist, BIBR277 (telmisartan) in hypertensive patients. Jpn Pharmacol Ther 2002; 30: S271-S283.
29. 1 receptor and beta 1-adrenoceptor antagonism. Eur J Pharmacol 2005; 520: 179-187.
30. Koh E, Morimoto S, Tomita J: Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 1994; 23: 175-179.
31. Browatzki M, Larsen D, Pfeiffer CAH: Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-κB and activator protein 1 in a redox-sensitive manner. J Vasc Res 2005; 42: 415-423.
32. Timmermans P: Pharmacologial properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15(suppl F): 26F-28F.
33. Maillard MP, Perregaux C, Centeno C, et al: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302: 1089-1095.
34. Fogari R: Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover pressure monitoring study. Curr Ther Res Clin Exp 2002; 63: 1-14.
35. Anderson OK: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59.